首页> 外国专利> IMMUNOTHERAPEUTIC AGENT AGAINST MULTIPLE MYELOMA, LEUKEMIA, MALIGNANT LYMPHOMA, LUNG CANCER OR THE LIKE

IMMUNOTHERAPEUTIC AGENT AGAINST MULTIPLE MYELOMA, LEUKEMIA, MALIGNANT LYMPHOMA, LUNG CANCER OR THE LIKE

机译：针对多发性骨髓瘤，白血病，恶性淋巴瘤，肺癌或类似疾病的免疫治疗剂

页面导航

摘要
著录项
相似文献

摘要

PPROBLEM TO BE SOLVED: To obtain an immunotherapeutic agent effective for treatment and prevention of metastasis and recurrence of malignant tumors of hematopoietic organs such as multiple myeloma, leukemia, malignant lymphoma, etc., and solid cancers such as lung cancer, breast cancer, etc., and to provide an immunotherapy using the preparation. PSOLUTION: The synthetic peptide is derived from human myeloma HM1.24 protein. The antigen has the peptide. The DNA molecule encodes the peptide. The dendritic cells are sensitized with the peptide or the antigen presenting cells are derived from the antigen. The cytotoxic T lymphocyte is derived from the peptide. The immunotherapeutic agent is excellently effective for treatment and prevention of metastasis and recurrence of malignant tumors of hematopoietic organs such as multiple myeloma, leukemia, malignant lymphoma, etc., and solid cancers such as lung cancer, breast cancer, etc., and is safe. PCOPYRIGHT: (C)2006,JPO&NCIPI

机译：

要解决的问题：获得一种有效治疗和预防造血器官恶性肿瘤（例如多发性骨髓瘤，白血病，恶性淋巴瘤等）和实体癌（例如肺癌，乳腺癌）的转移和复发的免疫治疗剂癌等，并提供使用该制剂的免疫疗法。

解决方案：合成肽衍生自人骨髓瘤HM1.24蛋白。抗原具有肽。 DNA分子编码肽。用肽敏化树突状细胞，或抗原呈递细胞衍生自抗原。细胞毒性T淋巴细胞衍生自该肽。该免疫治疗剂对于多发性骨髓瘤，白血病，恶性淋巴瘤等造血器官恶性肿瘤，肺癌，乳腺癌等实体癌的转移癌的预防，转移和复发非常有效，是安全的。。

版权：（C）2006，JPO＆NCIPI 展开▼

著录项

公开/公告号JP2006141208A

专利类型
公开/公告日2006-06-08

原文格式PDF
申请/专利权人 UNIV OF TOKUSHIMA;
展开▼

申请/专利号JP20040331569
发明设计人 OZAKI SHUJI;MATSUMOTO TOSHIO;
展开▼

申请日2004-11-16
分类号C12N15/09;A61K35/12;A61K39;A61P35;A61P35/02;C07K7/06;A61K38;C12N5/06;
国家 JP
入库时间 2022-08-21 21:53:04

相似文献

专利
外文文献
中文文献